A forensic evaluation of the national emphysema treatment trial using the expected value of information approach

Medical Care

Volumn 46, Issue 5, 2008, Pages 542-548

  Ramsey, Scott D ^a,b   Blough, David K ^a,b   Sullivan, Sean D ^b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Chronic obstructive pulmonary disease; Cost effectiveness; Economic analysis; Emphysema; Lung volume reduction surgery

Indexed keywords

ARTICLE; CLINICAL TRIAL; COST BENEFIT ANALYSIS; ECONOMICS; HUMAN; LUNG EMPHYSEMA; LUNG RESECTION; METHODOLOGY; MORTALITY; MULTICENTER STUDY; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; STATISTICAL MODEL; SURVIVAL; UNITED STATES;

COST-BENEFIT ANALYSIS; HUMANS; MODELS, ECONOMETRIC; PNEUMONECTOMY; PULMONARY EMPHYSEMA; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS; UNITED STATES;

EID: 42549137822     PISSN: 00257079     EISSN: None     Source Type: Journal    
DOI: 10.1097/MLR.0b013e318160b479     Document Type: Article

References (33)

1. Iglesias CP, Claxton K. Comprehensive decision-analytic model and Bayesian value-of-information analysis: pentoxifylline in the treatment of chronic venous leg ulcers. Pharmacoeconomics. 2006;24:465-478.
2. Fenwick E, Palmer S, Claxton K, et al. An iterative Bayesian approach to health technology assessment: application to a policy of preoperative optimization for patients undergoing major elective surgery. Med Decis Making. 2006;26:480-496.
3. Willan AR, Pinto EM. The value of information and optimal clinical trial design. Stat Med. 2005;24:1791-1806.
4. Fishman A, Martinez F, Naunheim K, et al. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med. 2003;348:2059-2073.
5. Cooper JD, Patterson GA. Lung-volume reduction surgery for severe emphysema. Chest Surg Clin N Am. 1995;5:815-831.
6. Huizenga HF, Ramsey SD, Albert RK. Estimated growth of lung volume reduction surgery among Medicare enrollees: 1994 to 1996. Chest. 1998;114:1583-1587.
7. Connors AF Jr, Dawson NV, Thomas C, et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). Am J Respir Crit Care Med. 1996;154(4 Pt 1):959-967.
8. Gentry C. Second opinion: why Medicare covers a new lung surgery for just a few patients. Wall Street Journal. 1998:A1.
9. Holohan TV, Handelsman H. Lung-volume reduction surgery for end-stage chronic obstructive pulmonary disease. Health Technol Assess (Rockv). 1996;10:1-30.
10. Ramsey SD, Sullivan SD. Evidence, economics, and emphysema: Medicare's long journey with lung volume reduction surgery. Health Aff (Millwood). 2005;24:55-66.
11. Ramsey SD, Berry K, Etzioni R, et al. Cost effectiveness of lung-volume-reduction surgery for patients with severe emphysema. N Engl J Med. 2003;348:2092-2102.
12. Raiffa H, Schlaifer R. Applied Statistical Decision Theory. New York, NY: John Wiley; 2000.
13. National Emphysema Treatment Trial Research Group. Rationale and design of the National Emphysema Treatment Trial (NETT): a prospective randomized trial of lung volume reduction surgery. J Thorac Cardiovasc Surg. 1999;118:518-528.
14. Traver GA, Cline MG, Burrows B. Predictors of mortality in chronic obstructive pulmonary disease. A 15-year follow-up study. Am Rev Respir Dis. 1979;119:895-902.
15. Dallari R, Barozzi G, Pinelli G, et al. Predictors of survival in subjects with chronic obstructive pulmonary disease treated with long-term oxygen therapy. Respiration. 1994;61:8-13.
16. Anthonisen NR, Wright EC, Hodgkin JE. Prognosis in chronic obstructive pulmonary disease. Am Rev Respir Dis. 1986;133:14-20.
17. Pardee NE, Winterbauer RH, Morgan EH, et al. Determination of mortality risk in obstructive pulmonary syndromes: physical examination compared with measurement of forced expired volume in one second. Thorax. 1981;36:928-931.
18. Skwarski K, MacNee W, Wraith PK, et al. Predictors of survival in patients with chronic obstructive pulmonary disease treated with long-term oxygen therapy. Chest. 1991;100:1522-1527.
19. Claxton K, Neumann PJ, Araki S, et al. Bayesian value-of-information analysis. An application to a policy model of Alzheimer's disease. Int J Technol Assess Health Care. 2001;17:38-55.
20. Miller JD, Malthaner RA, Goldsmith CH, et al. Lung volume reduction for emphysema and the Canadian Lung Volume Reduction Surgery (CLVR) Project. Can Respir J. 1999;6:26-32.
21. Claxton K. Bayesian approaches to the value of information: implications for the regulation of new pharmaceuticals. Health Econ. 1999;8:269-274.
22. O'Hagan A, Luce B. Bayesian Statistics in Health Economics and Outcomes Research: Bayesian Initiative in Health Economics and Outcomes Research. Sheffield, UK: Centre for Bayesian Statistics in Health Economics; 2006.
23. Hirth RA, Chernew ME, Miller E, et al. Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Making. 2000;20:332-342.
24. Pliskin JS, Stason WB, Weinstein MC, et al. Coronary artery bypass graft surgery: clinical decision making and cost-effectiveness analysis. Med Decis Making. 1981;1:10-28.
25. Weinstein MC, Stason WB. Cost-effectiveness of coronary artery bypass surgery. Circulation. 1982;66(5 Pt 2):III56-III66.
26. Ramsey SD, Patrick DL, Albert RK, et al. The cost-effectiveness of lung transplantation. A pilot study. University of Washington Medical Center Lung Transplant Study Group. Chest. 1995;108:1594-1601.
27. Al MJ, Koopmanschap MA, van Enckevort PJ, et al. Cost-effectiveness of lung transplantation in The Netherlands: a scenario analysis. Chest. 1998;113:124-130.
28. Owens DK, Sanders GD, Harris RA, et al. Cost-effectiveness of implantable cardioverter defibrillators relative to amiodarone for prevention of sudden cardiac death. Ann Intern Med. 1997;126:1-12.
29. Wagner JL, Alberts SR, Sloan JA, et al. Incremental costs of enrolling cancer patients in clinical trials: a population-based study. J Natl Cancer Inst. 1999;91:847-853.
30. Neumann PJ, Sullivan SD. Economic evaluation in the US: what is the missing link? Pharmacoeconomics. 2006;24:1163-1168.
31. Cooper JD. Paying the piper: the NETT strikes a sour note. National Emphysema Treatment Trial. Ann Thorac Surg. 2001;72:330-333.
32. Claxton KP, Sculpher MJ. Using value of information analysis to prioritise health research: some lessons from recent UK experience. Pharmacoeconomics. 2006;24:1055-1068.
33. Claxton K. The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. J Health Econ. 1999;18:341-364.